{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,9]],"date-time":"2026-10-09T06:09:47Z","timestamp":1791526187534,"version":"4.3.4"},"reference-count":141,"publisher":"MDPI AG","issue":"10","license":[{"start":{"date-parts":[[2026,5,7]],"date-time":"2026-05-07T00:00:00Z","timestamp":1778112000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100009687","name":"Wroclaw Medical University","doi-asserted-by":"crossref","award":["SUBD.D290.26.002"],"award-info":[{"award-number":["SUBD.D290.26.002"]}],"id":[{"id":"10.13039\/501100009687","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/501100009687","name":"Wroclaw Medical University","doi-asserted-by":"crossref","award":["SUBZ.D070.26.006"],"award-info":[{"award-number":["SUBZ.D070.26.006"]}],"id":[{"id":"10.13039\/501100009687","id-type":"DOI","asserted-by":"crossref"}]},{"award":["SUBD.D290.26.002"],"award-info":[{"award-number":["SUBD.D290.26.002"]}],"id":[{"id":"https:\/\/ror.org\/01qpw1b93","id-type":"ROR","asserted-by":"publisher"}]},{"award":["SUBZ.D070.26.006"],"award-info":[{"award-number":["SUBZ.D070.26.006"]}],"id":[{"id":"https:\/\/ror.org\/01qpw1b93","id-type":"ROR","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["IJMS"],"abstract":"<jats:p>Cancers are intricate and multifactorial diseases. Despite progress in medicine, there are still some obstacles in their treatment due to drug resistance, the toxicity of combination therapy and lack of drug selectivity toward cancer cells. The solution to this may be multi-target directed ligands (MTDLs), which have gained more and more popularity over the years. This review presents a comprehensive overview of novel potential multi-targeted derivatives of nitrogen-containing heterocycles, as imidazole, pyrazole, 1,2,3-triazole and 1,2,4-triazole. The review gathers the selected literature from 2006 to 2026. The analysis focuses on the potency of the inhibitory activity of selected molecules against a variety of molecular targets, as well as on their interactions with protein binding sites. Additionally, the structure-activity relationship (SAR) studies within the collected series are included. The discussion may contribute to the development of new multi-target anticancer agents.<\/jats:p>","DOI":"10.3390\/ijms27104172","type":"journal-article","created":{"date-parts":[[2026,5,8]],"date-time":"2026-05-08T19:10:52Z","timestamp":1778267452000},"page":"4172","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["Diversity and Multi-Target Potential of Pyrazole, Imidazole or Triazole Derivatives in Modern Anticancer Therapy"],"prefix":"10.3390","volume":"27","author":[{"given":"Martyna","family":"Mys\u0142ek","sequence":"first","affiliation":[{"name":"Department of Basic Chemical Sciences, Faculty of Pharmacy, Wroclaw Medical University, Borowska 211a, 50-556 Wroclaw, Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0007-5192-8844","authenticated-orcid":false,"given":"Anna","family":"Kaczmarek","sequence":"additional","affiliation":[{"name":"Department of Medicinal Chemistry, Faculty of Pharmacy, Wroclaw Medical University, Borowska 211a, 50-556 Wroclaw, Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4613-025X","authenticated-orcid":false,"given":"Piotr","family":"\u015awi\u0105tek","sequence":"additional","affiliation":[{"name":"Department of Medicinal Chemistry, Faculty of Pharmacy, Wroclaw Medical University, Borowska 211a, 50-556 Wroclaw, Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5758-9667","authenticated-orcid":false,"given":"\u017baneta","family":"Czy\u017cnikowska","sequence":"additional","affiliation":[{"name":"Department of Basic Chemical Sciences, Faculty of Pharmacy, Wroclaw Medical University, Borowska 211a, 50-556 Wroclaw, Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2026,5,7]]},"reference":[{"key":"ref_1","first-page":"229","article-title":"Global Cancer Statistics 2022: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries","volume":"74","author":"Bray","year":"2024","journal-title":"CA Cancer J. Clin."},{"key":"ref_2","doi-asserted-by":"crossref","unstructured":"Sadula, A., and Gaddhe, L. (2023). Synthesis, Computational Studies and Biological Evaluation of Novel Acenaphthoquinone-Imidazole Derivatives as Dual Inhibitors of HSP90 and Topo II in Cancer Therapy. Results Chem., 5.","DOI":"10.1016\/j.rechem.2023.100796"},{"key":"ref_3","doi-asserted-by":"crossref","unstructured":"Liu, J., Ye, W., Xu, J.-P., Wang, H.-T., Li, X.-F., Wang, W.-Y., and Zhou, Z.-Z. (2021). Discovery of Novel Trimethoxyphenylbenzo[d]Oxazoles as Dual Tubulin\/PDE4 Inhibitors Capable of Inducing Apoptosis at G2\/M Phase Arrest in Glioma and Lung Cancer Cells. Eur. J. Med. Chem., 224.","DOI":"10.1016\/j.ejmech.2021.113700"},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"38022","DOI":"10.18632\/oncotarget.16723","article-title":"Combination Therapy in Combating Cancer","volume":"8","author":"Mokhtari","year":"2017","journal-title":"Oncotarget"},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"3235","DOI":"10.2147\/DDDT.S257494","article-title":"Potential Impact of the Multi-Target Drug Approach in the Treatment of Some Complex Diseases","volume":"14","author":"Makhoba","year":"2020","journal-title":"Drug Des. Dev. Ther."},{"key":"ref_6","doi-asserted-by":"crossref","unstructured":"Doostmohammadi, A., Jooya, H., Ghorbanian, K., Gohari, S., and Dadashpour, M. (2024). Potentials and Future Perspectives of Multi-Target Drugs in Cancer Treatment: The Next Generation Anti-Cancer Agents. Cell Commun. Signal., 22.","DOI":"10.1186\/s12964-024-01607-9"},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1038\/nrclinonc.2016.96","article-title":"Combine and Conquer: Challenges for Targeted Therapy Combinations in Early Phase Trials","volume":"14","author":"Lopez","year":"2017","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"ref_8","first-page":"3034","article-title":"Approval Summary: Imatinib Mesylate in the Treatment of Metastatic and\/or Unresectable Malignant Gastrointestinal Stromal Tumors","volume":"8","author":"Dagher","year":"2002","journal-title":"Clin. Cancer Res."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"835","DOI":"10.1038\/nrd2130","article-title":"Discovery and Development of Sorafenib: A Multikinase Inhibitor for Treating Cancer","volume":"5","author":"Wilhelm","year":"2006","journal-title":"Nat. Rev. Drug Discov."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1016\/S1470-2045(08)70285-7","article-title":"Efficacy and Safety of Sorafenib in Patients in the Asia-Pacific Region with Advanced Hepatocellular Carcinoma: A Phase III Randomised, Double-Blind, Placebo-Controlled Trial","volume":"10","author":"Cheng","year":"2009","journal-title":"Lancet Oncol."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1016\/S0140-6736(14)60421-9","article-title":"Sorafenib in Radioactive Iodine-Refractory, Locally Advanced or Metastatic Differentiated Thyroid Cancer: A Randomised, Double-Blind, Phase 3 Trial","volume":"384","author":"Brose","year":"2014","journal-title":"Lancet"},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1634\/theoncologist.2016-0197","article-title":"Sunitinib: Ten Years of Successful Clinical Use and Study in Advanced Renal Cell Carcinoma","volume":"22","author":"Motzer","year":"2017","journal-title":"Oncologist"},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"1108","DOI":"10.1634\/theoncologist.2012-0044","article-title":"FDA Approval Summary: Sunitinib for the Treatment of Progressive Well-Differentiated Locally Advanced or Metastatic Pancreatic Neuroendocrine Tumors","volume":"17","author":"Blumenthal","year":"2012","journal-title":"Oncologist"},{"key":"ref_14","doi-asserted-by":"crossref","unstructured":"Kabir, E., and Uzzaman, M. (2022). A Review on Biological and Medicinal Impact of Heterocyclic Compounds. Results Chem., 4.","DOI":"10.1016\/j.rechem.2022.100606"},{"key":"ref_15","doi-asserted-by":"crossref","unstructured":"Baaloudj, O., Scrano, L., Bufo, S.A., Modley, L.-A.S., Lelario, F., Zizzamia, A.R., Emanuele, L., and Brienza, M. (2025). Environmental Fate, Ecotoxicity, and Remediation of Heterocyclic Pharmaceuticals as Emerging Contaminants: A Review of Long-Term Risks and Impacts. Organics, 6.","DOI":"10.3390\/org6010001"},{"key":"ref_16","doi-asserted-by":"crossref","unstructured":"Ma, C., Zhang, H., Liu, Z., Meng, X., Chen, S., Zhang, J., Li, Y., and Huang, X. (2025). Treatment Options of Nitrogen Heterocyclic Compounds in Industrial Wastewater: From Fundamental Technologies to Energy Valorization Applications and Future Process Design Strategies. Water Res., 281.","DOI":"10.1016\/j.watres.2025.123575"},{"key":"ref_17","doi-asserted-by":"crossref","unstructured":"Bian, Y., Zhang, Y., Zou, P., Zhou, Y., Feng, X., and Wang, J. (2025). Triazoles in the Environment: An Update on Occurrence, Fate, Health Hazards, and Removal Techniques. Environ. Res., 271.","DOI":"10.1016\/j.envres.2025.121092"},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"2417","DOI":"10.1056\/NEJMoa1805052","article-title":"Sorafenib for Advanced and Refractory Desmoid Tumors","volume":"379","author":"Gounder","year":"2018","journal-title":"N. Engl. J. Med."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"331","DOI":"10.5306\/wjco.v7.i4.331","article-title":"Sorafenib in Breast Cancer Treatment: A Systematic Review and Overview of Clinical Trials","volume":"7","author":"Zafrakas","year":"2016","journal-title":"World J. Clin. Oncol."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"899","DOI":"10.1002\/jhet.4588","article-title":"Nitrogen-containing Heterocycles as Topoisomerase II Inhibitors for Targeting Cancer: Recent Updates","volume":"60","author":"Sahu","year":"2023","journal-title":"J. Heterocycl. Chem."},{"key":"ref_21","doi-asserted-by":"crossref","unstructured":"Kumar, A., Singh, A.K., Singh, H., Vijayan, V., Kumar, D., Naik, J., Thareja, S., Yadav, J.P., Pathak, P., and Grishina, M. (2023). Nitrogen Containing Heterocycles as Anticancer Agents: A Medicinal Chemistry Perspective. Pharmaceuticals, 16.","DOI":"10.3390\/ph16020299"},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1007\/s40265-018-1041-0","article-title":"Lorlatinib: First Global Approval","volume":"79","author":"Syed","year":"2019","journal-title":"Drugs"},{"key":"ref_23","first-page":"333","article-title":"Axitinib: Newly Approved for Renal Cell Carcinoma","volume":"3","author":"Tyler","year":"2012","journal-title":"J. Adv. Pract. Oncol."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"1903","DOI":"10.1007\/s40265-015-0483-x","article-title":"Axitinib: A Review in Advanced Renal Cell Carcinoma","volume":"75","author":"Keating","year":"2015","journal-title":"Drugs"},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"1247","DOI":"10.2147\/TCRM.S147381","article-title":"Entrectinib: An Orally Available, Selective Tyrosine Kinase Inhibitor for the Treatment of NTRK, ROS1, and ALK Fusion-Positive Solid Tumors","volume":"14","author":"Liu","year":"2018","journal-title":"Ther. Clin. Risk Manag."},{"key":"ref_26","doi-asserted-by":"crossref","unstructured":"Krishnapriya, K.R., Hacholli, V.B., Gackowski, M., Pisklak, D.M., Kumar, A., and Szeleszczuk, \u0141. (2026). The Pyrazole Scaffold in Anticancer Drug Discovery: A Review of Synthetic Approaches, Structure\u2013Activity Relationships, and Target-Based Mechanism of Action. Int. J. Mol. Sci., 27.","DOI":"10.3390\/ijms27083403"},{"key":"ref_27","doi-asserted-by":"crossref","unstructured":"Naeem, N., Mughal, E.U., Sadiq, A., Othman, G.A., and Shakoor, B. (2025). Recent Advances in 1,2,4-Triazole-Based Anticancer Agents: Structural Optimization, Mechanisms, and Therapeutic Potential (2022\u20132025). Arch. Pharm., 358.","DOI":"10.1002\/ardp.70059"},{"key":"ref_28","doi-asserted-by":"crossref","unstructured":"Huang, S., Xu, Z., and Zhuang, Y. (2025). The Current Landscape of 1,2,3-Triazole Hybrids with Anticancer Therapeutic Potential: Part I. Arch. Pharm., 358.","DOI":"10.1002\/ardp.202500001"},{"key":"ref_29","doi-asserted-by":"crossref","unstructured":"Xu, Z., and Liu, J. (2025). The Current Landscape of 1,2,3-Triazole Hybrids with Anticancer Therapeutic Potential: Part II. Arch. Pharm., 358.","DOI":"10.1002\/ardp.202500031"},{"key":"ref_30","doi-asserted-by":"crossref","unstructured":"Tilly, D.P., Heeb, J.-P., Webb, S.J., and Clayden, J. (2023). Switching Imidazole Reactivity by Dynamic Control of Tautomer State in an Allosteric Foldamer. Nat. Commun., 14, Correction in Nat. Commun. 2024, 15, 9327. https:\/\/doi.org\/10.1038\/s41467-024-53247-9.","DOI":"10.1038\/s41467-024-53247-9"},{"key":"ref_31","doi-asserted-by":"crossref","unstructured":"Sharma, P., LaRosa, C., Antwi, J., Govindarajan, R., and Werbovetz, K.A. (2021). Imidazoles as Potential Anticancer Agents: An Update on Recent Studies. Molecules, 26.","DOI":"10.3390\/molecules26144213"},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"805","DOI":"10.1016\/j.ejmech.2004.05.005","article-title":"Ring-Substituted Imidazoles as a New Class of Anti-Tuberculosis Agents","volume":"39","author":"Gupta","year":"2004","journal-title":"Eur. J. Med. Chem."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"1380","DOI":"10.2174\/1389557520999201209213648","article-title":"Imidazole Derivatives and Their Antibacterial Activity\u2014A Mini-Review","volume":"21","author":"Andrei","year":"2021","journal-title":"Mini-Rev. Med. Chem."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"1399","DOI":"10.1016\/j.biopha.2019.01.052","article-title":"New Pre-Clinical Evidence of Anti-Inflammatory Effect and Safety of a Substituted Fluorophenyl Imidazole","volume":"111","author":"Fratoni","year":"2019","journal-title":"Biomed. Pharmacother."},{"key":"ref_35","first-page":"88","article-title":"A Review on Imidazole Derivatives Having Appropriate Remedies for Extreme Diseases","volume":"62","author":"Renjima","year":"2020","journal-title":"Int. J. Pharm. Sci. Rev. Res."},{"key":"ref_36","first-page":"107","article-title":"Development of the Basics of Production Technology of Dacarbazine Substance with Anticancer Effect","volume":"7","author":"Stasevych","year":"2024","journal-title":"Chem. Technol. Appl. Subst."},{"key":"ref_37","doi-asserted-by":"crossref","unstructured":"Gao, Y., Ding, Y., Tai, X., Zhang, C., and Wang, D. (2023). Ponatinib: An Update on Its Drug Targets, Therapeutic Potential and Safety. Biochim. Biophys. Acta Rev. Cancer, 1878.","DOI":"10.1016\/j.bbcan.2023.188949"},{"key":"ref_38","unstructured":"Doucet, K.G. (2007). Dacarbazine and Its Structural Analogues: Systematic Computational Studies of the Configurations, Tautomers, Tautomerization Pathways and Bimolecular Nucleophilic Substitution Reaction Mechanisms of Dacarbazine: A Triazene Containing Anti-Neoplastic Agent, and Its Structural Analogues. [Master\u2019s Thesis, Saint Mary\u2019s University]."},{"key":"ref_39","doi-asserted-by":"crossref","unstructured":"Nascimento, M., Moura, S., Parra, L., Vasconcellos, V., Costa, G., Leite, D., Dias, M., Fernandes, T.V.A., Hoelz, L., and Pimentel, L. (2024). Ponatinib: A Review of the History of Medicinal Chemistry behind Its Development. Pharmaceuticals, 17.","DOI":"10.3390\/ph17101361"},{"key":"ref_40","doi-asserted-by":"crossref","unstructured":"Ceci, C., Atzori, M.G., Lacal, P.M., and Graziani, G. (2020). Role of VEGFs\/VEGFR-1 Signaling and Its Inhibition in Modulating Tumor Invasion: Experimental Evidence in Different Metastatic Cancer Models. Int. J. Mol. Sci., 21.","DOI":"10.3390\/ijms21041388"},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"1440","DOI":"10.1016\/j.bmcl.2005.11.033","article-title":"Hetaryl Imidazoles: A Novel Dual Inhibitors of VEGF Receptors I and II","volume":"16","author":"Kiselyov","year":"2006","journal-title":"Bioorg. Med. Chem. Lett."},{"key":"ref_42","doi-asserted-by":"crossref","unstructured":"Othman, D.I.A., Hamdi, A., Tawfik, S.S., Elgazar, A.A., and Mostafa, A.S. (2023). Identification of New Benzimidazole-Triazole Hybrids as Anticancer Agents: Multi-Target Recognition, in Vitro and in Silico Studies. J. Enzyme Inhib. Med. Chem., 38.","DOI":"10.1080\/14756366.2023.2166037"},{"key":"ref_43","doi-asserted-by":"crossref","unstructured":"Uribe, M.L., Marrocco, I., and Yarden, Y. (2021). EGFR in Cancer: Signaling Mechanisms, Drugs, and Acquired Resistance. Cancers, 13.","DOI":"10.3390\/cancers13112748"},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"6589","DOI":"10.1007\/s11033-021-06665-7","article-title":"Regulation of Topoisomerase II Stability and Activity by Ubiquitination and SUMOylation: Clinical Implications for Cancer Chemotherapy","volume":"48","author":"Ma","year":"2021","journal-title":"Mol. Biol. Rep."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"28889","DOI":"10.1039\/D4RA05462H","article-title":"Benzimidazole\u2013Dioxoisoindoline Conjugates as Dual VEGFR-2 and FGFR-1 Inhibitors: Design, Synthesis, Biological Investigation, Molecular Docking Studies and ADME Predictions","volume":"14","author":"Nageeb","year":"2024","journal-title":"RSC Adv."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1080\/19336918.2020.1766308","article-title":"FGFR1 Regulates Proliferation and Metastasis by Targeting CCND1 in FGFR1 Amplified Lung Cancer","volume":"14","author":"Yang","year":"2020","journal-title":"Cell Adhes. Migr."},{"key":"ref_47","doi-asserted-by":"crossref","unstructured":"Abdel-Mohsen, H.T., Ibrahim, M.A., Nageeb, A.M., and El Kerdawy, A.M. (2024). Receptor-Based Pharmacophore Modeling, Molecular Docking, Synthesis and Biological Evaluation of Novel VEGFR-2, FGFR-1, and BRAF Multi-Kinase Inhibitors. BMC Chem., 18.","DOI":"10.1186\/s13065-024-01135-0"},{"key":"ref_48","doi-asserted-by":"crossref","unstructured":"Abdel-Mohsen, H.T., Syam, Y.M., Abd El-Ghany, M.S., and Abd El-Karim, S.S. (2024). Benzimidazole-oxindole Hybrids: A Novel Class of Selective Dual CDK2 and GSK-3\u03b2 Inhibitors of Potent Anticancer Activity. Arch. Pharm., 357.","DOI":"10.1002\/ardp.202300721"},{"key":"ref_49","doi-asserted-by":"crossref","unstructured":"Zhang, J., Gan, Y., Li, H., Yin, J., He, X., Lin, L., Xu, S., Fang, Z., Kim, B., and Gao, L. (2022). Inhibition of the CDK2 and Cyclin A Complex Leads to Autophagic Degradation of CDK2 in Cancer Cells. Nat. Commun., 13.","DOI":"10.1038\/s41467-022-30264-0"},{"key":"ref_50","doi-asserted-by":"crossref","unstructured":"Thapa, R., Gupta, G., Bhat, A.A., Almalki, W.H., Alzarea, S.I., Kazmi, I., Saleem, S., Khan, R., Altwaijry, N., and Dureja, H. (2023). A Review of Glycogen Synthase Kinase-3 (GSK3) Inhibitors for Cancers Therapies. Int. J. Biol. Macromol., 253.","DOI":"10.1016\/j.ijbiomac.2023.127375"},{"key":"ref_51","doi-asserted-by":"crossref","unstructured":"Ali, I.H., Abdel-Mohsen, H.T., Mounier, M.M., Abo-elfadl, M.T., El Kerdawy, A.M., and Ghannam, I.A.Y. (2022). Design, Synthesis and Anticancer Activity of Novel 2-Arylbenzimidazole\/2-Thiopyrimidines and 2-Thioquinazolin-4(3H)-Ones Conjugates as Targeted RAF and VEGFR-2 Kinases Inhibitors. Bioorg. Chem., 126.","DOI":"10.1016\/j.bioorg.2022.105883"},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"4618","DOI":"10.1158\/1078-0432.CCR-21-2138","article-title":"Molecular Pathways and Mechanisms of BRAF in Cancer Therapy","volume":"28","author":"Poulikakos","year":"2022","journal-title":"Clin. Cancer Res."},{"key":"ref_53","doi-asserted-by":"crossref","unstructured":"Wang, P., Laster, K., Jia, X., Dong, Z., and Liu, K. (2023). Targeting CRAF Kinase in Anti-Cancer Therapy: Progress and Opportunities. Mol. Cancer, 22.","DOI":"10.1186\/s12943-023-01903-x"},{"key":"ref_54","doi-asserted-by":"crossref","unstructured":"Lamie, P.F., Halim, P.A., Sayed, A.M., Kahk, N.M., Abdelhakeem, M.M., and Mohamed, F.E.A. (2025). Indole-Imidazolone Derivatives as Dual Mcl-1\/COX-2 Inhibitors: Design-Oriented Synthesis, Molecular Docking, and Dynamics Studies with Potential Anticancer and Anti-Inflammatory Activities. Bioorg. Chem., 165.","DOI":"10.1016\/j.bioorg.2025.108962"},{"key":"ref_55","doi-asserted-by":"crossref","unstructured":"Fadaly, W.A.A., Elshaier, Y.A.M.M., Nemr, M.T.M., and Abdellatif, K.R.A. (2023). Design, Synthesis, Modeling Studies and Biological Evaluation of Pyrazole Derivatives Linked to Oxime and Nitrate Moieties as Nitric Oxide Donor Selective COX-2 and Aromatase Inhibitors with Dual Anti-Inflammatory and Anti-Neoplastic Activities. Bioorg. Chem., 134.","DOI":"10.1016\/j.bioorg.2023.106428"},{"key":"ref_56","doi-asserted-by":"crossref","unstructured":"Soltan, O.M., Abdel-Aziz, S.A., Abdelrahman, K.S., Narumi, A., Abdel-Aziz, M., Shoman, M.E., and Konno, H. (2026). Design, Synthesis, and Biological Evaluation of Novel 1,5-Diarylpyrazole Carboxamides with Dual Inhibition of EGFR and COX-2 for the Treatment of Cancer and Inflammatory Diseases. Bioorg. Med. Chem. Lett., 130.","DOI":"10.1016\/j.bmcl.2025.130416"},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1016\/j.pharmthera.2019.02.007","article-title":"Recent Advances in the Development of Mcl-1 Inhibitors for Cancer Therapy","volume":"198","author":"Hird","year":"2019","journal-title":"Pharmacol. Ther."},{"key":"ref_58","doi-asserted-by":"crossref","unstructured":"Li, C., Han, Y., Wang, Z., Yu, Y., Wang, C., Ren, Z., Guo, Y., Zhu, T., Li, X., and Dong, S. (2023). Function-Oriented Synthesis of Imidazo[1,2-a]Pyrazine and Imidazo[1,2-b]Pyridazine Derivatives as Potent PI3K\/MTOR Dual Inhibitors. Eur. J. Med. Chem., 247.","DOI":"10.1016\/j.ejmech.2022.115030"},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"4587","DOI":"10.1007\/s11033-020-05435-1","article-title":"Role of PI3K\/AKT Pathway in Cancer: The Framework of Malignant Behavior","volume":"47","author":"Jiang","year":"2020","journal-title":"Mol. Biol. Rep."},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1186\/s13578-020-00396-1","article-title":"MTOR Signaling Pathway and MTOR Inhibitors in Cancer: Progress and Challenges","volume":"10","author":"Zou","year":"2020","journal-title":"Cell Biosci."},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1016\/j.jphotobiol.2017.09.010","article-title":"EGFR, HER2 Target Based Molecular Docking Analysis, in Vitro Screening of 2, 4, 5-Trisubstituted Imidazole Derivatives as Potential Anti-Oxidant and Cytotoxic Agents","volume":"176","author":"Guda","year":"2017","journal-title":"J. Photochem. Photobiol. B Biol."},{"key":"ref_62","doi-asserted-by":"crossref","unstructured":"Zhu, K., Yang, X., Tai, H., Zhong, X., Luo, T., and Zheng, H. (2024). HER2-Targeted Therapies in Cancer: A Systematic Review. Biomark. Res., 12.","DOI":"10.1186\/s40364-024-00565-1"},{"key":"ref_63","doi-asserted-by":"crossref","unstructured":"Dokla, E.M.E., Abdel-Aziz, A.K., Milik, S.N., McPhillie, M.J., Minucci, S., and Abouzid, K.A.M. (2022). Discovery of a Benzimidazole-Based Dual FLT3\/TrKA Inhibitor Targeting Acute Myeloid Leukemia. Bioorg. Med. Chem., 56.","DOI":"10.1016\/j.bmc.2021.116596"},{"key":"ref_64","doi-asserted-by":"crossref","unstructured":"Abd El-Sattar, N.E.A., Badawy, E.H.K., and Abdel-Mottaleb, M.S.A. (2018). Synthesis of Some Pyrimidine, Pyrazole, and Pyridine Derivatives and Their Reactivity Descriptors. J. Chem., 2018.","DOI":"10.1155\/2018\/8795061"},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"3693","DOI":"10.1021\/jm030394f","article-title":"Synthesis and Antibacterial Activity of a Novel Series of Potent DNA Gyrase Inhibitors. Pyrazole Derivatives","volume":"47","author":"Tanitame","year":"2004","journal-title":"J. Med. Chem."},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"3746","DOI":"10.1016\/j.ejmech.2009.03.038","article-title":"Synthesis and Antiviral Activity of New Pyrazole and Thiazole Derivatives","volume":"44","author":"Baraka","year":"2009","journal-title":"Eur. J. Med. Chem."},{"key":"ref_67","doi-asserted-by":"crossref","unstructured":"Kamani, R., Raval, D., Patel, K., Prajapati, V., Prajapati, R., Shah, U., Patel, N., Patel, A., Patel, M., and Mali, S.N. (2025). One-Pot Multicomponent Synthesis of Novel Pyrazole-Linked Thiazolyl-Pyrazolines: Molecular Docking and Cytotoxicity Assessment on Breast and Lung Cancer Cell-Lines. J. Mol. Struct., 1322.","DOI":"10.1016\/j.molstruc.2024.140295"},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"332","DOI":"10.1016\/j.ejmech.2019.03.052","article-title":"New Pyrazole Derivatives: Synthesis, Anti-Inflammatory Activity, Cycloxygenase Inhibition Assay and Evaluation of MPGES","volume":"171","author":"Hassan","year":"2019","journal-title":"Eur. J. Med. Chem."},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1002\/ajh.24976","article-title":"Ruxolitinib-associated Infections: A Systematic Review and Meta-analysis","volume":"93","author":"Lussana","year":"2018","journal-title":"Am. J. Hematol."},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"1277","DOI":"10.1007\/s40265-018-0963-x","article-title":"Encorafenib and Binimetinib: First Global Approvals","volume":"78","author":"Shirley","year":"2018","journal-title":"Drugs"},{"key":"ref_71","doi-asserted-by":"crossref","unstructured":"Attwa, M.W., Darwish, H.W., Al-Shakliah, N.S., and Kadi, A.A. (2021). A Validated LC\u2013MS\/MS Assay for the Simultaneous Quantification of the FDA-Approved Anticancer Mixture (Encorafenib and Binimetinib): Metabolic Stability Estimation. Molecules, 26.","DOI":"10.3390\/molecules26092717"},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"559","DOI":"10.1007\/s40262-023-01225-7","article-title":"Pharmacokinetics and Pharmacodynamics of Ruxolitinib: A Review","volume":"62","author":"Appeldoorn","year":"2023","journal-title":"Clin. Pharmacokinet."},{"key":"ref_73","doi-asserted-by":"crossref","unstructured":"Fadaly, W.A.A., Nemr, M.T.M., Abd El-Hameed, A.M., Mohamed, F.E.A., and Zidan, T.H. (2025). Design and Synthesis of New Pyrazole Hybrids Linked to Oxime and Nitrate Moieties as COX-2, EGFRL858R\/T790M Inhibitors and Nitric Oxide Donors with Dual Anti-Inflammatory\/Anti-Proliferative Activities. Bioorg. Chem., 161.","DOI":"10.1016\/j.bioorg.2025.108563"},{"key":"ref_74","doi-asserted-by":"crossref","unstructured":"Kharb, R., Haider, K., Neha, K., and Yar, M.S. (2020). Aromatase Inhibitors: Role in Postmenopausal Breast Cancer. Arch. Pharm., 353.","DOI":"10.1002\/ardp.202000081"},{"key":"ref_75","doi-asserted-by":"crossref","unstructured":"Boshta, N.M., Temirak, A., El-Shahid, Z.A., Shafiq, Z., and Soliman, A.A.F. (2024). Design, Synthesis, Molecular Docking and Biological Evaluation of 1,3,5-Trisubstituted-1H-Pyrazole Derivatives as Anticancer Agents with Cell Cycle Arrest, ERK and RIPK3- Kinase Activities. Bioorg. Chem., 143.","DOI":"10.1016\/j.bioorg.2023.107058"},{"key":"ref_76","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1158\/1541-7786.MCR-20-0687","article-title":"The MEK\/ERK Network as a Therapeutic Target in Human Cancer","volume":"19","author":"Barbosa","year":"2021","journal-title":"Mol. Cancer Res."},{"key":"ref_77","doi-asserted-by":"crossref","first-page":"7199","DOI":"10.1007\/s00018-021-03947-y","article-title":"RIPK3 Signaling and Its Role in the Pathogenesis of Cancers","volume":"78","author":"Liu","year":"2021","journal-title":"Cell. Mol. Life Sci."},{"key":"ref_78","doi-asserted-by":"crossref","first-page":"6205","DOI":"10.1007\/s11030-025-11121-w","article-title":"Design and Synthesis of Novel Pyrimidine-Pyrazole Hybrids with Dual Anticancer and Anti-Inflammatory Effects Targeting BRAFV600E and JNK","volume":"29","author":"Eitah","year":"2025","journal-title":"Mol. Divers."},{"key":"ref_79","doi-asserted-by":"crossref","first-page":"574","DOI":"10.1080\/14756366.2020.1720013","article-title":"Selective Inhibitors for JNK Signalling: A Potential Targeted Therapy in Cancer","volume":"35","author":"Wu","year":"2020","journal-title":"J. Enzyme Inhib. Med. Chem."},{"key":"ref_80","doi-asserted-by":"crossref","unstructured":"Salem, M.G., Nafie, M.S., Elzamek, A.A., Elshihawy, H.A., Sofan, M.A., and Negm, E. (2024). Design, Synthesis, and Biological Investigations of New Pyrazole Derivatives as VEGFR2\/CDK-2 Inhibitors Targeting Liver Cancer. BMC Chem., 18.","DOI":"10.1186\/s13065-024-01314-z"},{"key":"ref_81","doi-asserted-by":"crossref","first-page":"40078","DOI":"10.1039\/D5RA06852E","article-title":"Design, Synthesis, and Anticancer Evaluation of Novel Pyrazole\u2013Thiophene Hybrid Derivatives as Multitarget Inhibitors of Wild EGFR, Mutant (T790M) EGFR, and VEGFR-2","volume":"15","author":"Sallam","year":"2025","journal-title":"RSC Adv."},{"key":"ref_82","doi-asserted-by":"crossref","unstructured":"Alhamaky, S.M., Khalil, N.A., Bass, A.K.A., Osama, N., and Hassan, M.S.A. (2025). Design, Synthesis, Docking Studies, and Investigation of Dual EGFR\/VEGFR-2 Inhibitory Potentials of New Pyrazole and Pyrazolopyridine Derivatives. Drug Dev. Res., 86.","DOI":"10.1002\/ddr.70056"},{"key":"ref_83","doi-asserted-by":"crossref","first-page":"1243","DOI":"10.1021\/acs.jmedchem.0c02111","article-title":"Discovery of Novel Pyrrolo[2,3-d]Pyrimidine-Based Derivatives as Potent JAK\/HDAC Dual Inhibitors for the Treatment of Refractory Solid Tumors","volume":"65","author":"Liang","year":"2022","journal-title":"J. Med. Chem."},{"key":"ref_84","doi-asserted-by":"crossref","first-page":"769","DOI":"10.1038\/nrd2133","article-title":"Anticancer Activities of Histone Deacetylase Inhibitors","volume":"5","author":"Bolden","year":"2006","journal-title":"Nat. Rev. Drug Discov."},{"key":"ref_85","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1080\/17568919.2024.2437975","article-title":"A Short Overview of Dual Targeting HDAC Inhibitors","volume":"17","author":"Liu","year":"2025","journal-title":"Future Med. Chem."},{"key":"ref_86","doi-asserted-by":"crossref","unstructured":"Li, X., Yang, T., Hu, M., Yang, Y., Tang, M., Deng, D., Liu, K., Fu, S., Tan, Y., and Wang, H. (2022). Synthesis and Biological Evaluation of 6-(Pyrimidin-4-yl)-1H-Pyrazolo[4,3-b]Pyridine Derivatives as Novel Dual FLT3\/CDK4 Inhibitors. Bioorg. Chem., 121.","DOI":"10.1016\/j.bioorg.2022.105669"},{"key":"ref_87","doi-asserted-by":"crossref","unstructured":"Couto Rodrigues, S., Silva Morat\u00f3rio de Moraes, R., Tavares de Almeida Pinto, G., Miranda Martins, M.T., Antunes do Nascimento, P., Alves Soares, D.L., Mestre Botelho, A.B., Cardoso Cruz, C., and Cunha, A.C. (2025). A Review on Chemistry and Methods of Synthesis of 1,2,4-Triazole Derivatives. Chem. Rec., 25.","DOI":"10.1002\/tcr.202400190"},{"key":"ref_88","doi-asserted-by":"crossref","unstructured":"Khan, J., Rani, A., Aslam, M., Maharia, R.S., Pandey, G., and Nand, B. (2024). Exploring Triazole-Based Drugs: Synthesis, Application, FDA Approvals, and Clinical Trial Updates\u2014A Comprehensive Review. Tetrahedron, 162.","DOI":"10.1016\/j.tet.2024.134122"},{"key":"ref_89","doi-asserted-by":"crossref","first-page":"1346","DOI":"10.1080\/14756366.2022.2072308","article-title":"New 1,2,3-Triazole Linked Ciprofloxacin-Chalcones Induce DNA Damage by Inhibiting Human Topoisomerase I&II and Tubulin Polymerization","volume":"37","author":"Mohammed","year":"2022","journal-title":"J. Enzyme Inhib. Med. Chem."},{"key":"ref_90","doi-asserted-by":"crossref","unstructured":"Kassem, A.F., Omar, M.A., Nossier, E.S., Awad, H.M., and El-Sayed, W.A. (2023). Novel Pyridine-Thiazolidinone-Triazole Hybrid Glycosides Targeting EGFR and CDK-2: Design, Synthesis, Anticancer Evaluation, and Molecular Docking Simulation. J. Mol. Struct., 1294.","DOI":"10.1016\/j.molstruc.2023.136358"},{"key":"ref_91","doi-asserted-by":"crossref","unstructured":"Silva, T.B., Ji, K.N., Pauli, F.P., Galv\u00e3o, R.M., Faria, A.F., Bello, M.L., Resende, J.A., Campos, V.R., Forezi, L.d.S., and Silva, F.d.C.d. (2021). Synthesis and in Vitro and in Silico Studies of 1H- and 2H-1,2,3-Triazoles as Antichagasic Agents. Bioorg. Chem., 116.","DOI":"10.1016\/j.bioorg.2021.105250"},{"key":"ref_92","doi-asserted-by":"crossref","unstructured":"Xu, Z., Zhao, S.-J., and Liu, Y. (2019). 1,2,3-Triazole-Containing Hybrids as Potential Anticancer Agents: Current Developments, Action Mechanisms and Structure-Activity Relationships. Eur. J. Med. Chem., 183.","DOI":"10.1016\/j.ejmech.2019.111700"},{"key":"ref_93","doi-asserted-by":"crossref","first-page":"2596","DOI":"10.1002\/1521-3773(20020715)41:14<2596::AID-ANIE2596>3.0.CO;2-4","article-title":"A Stepwise Huisgen Cycloaddition Process: Copper(I)-Catalyzed Regioselective \u201cLigation\u201d of Azides and Terminal Alkynes","volume":"41","author":"Rostovtsev","year":"2002","journal-title":"Angew. Chem. Int. Ed. Engl."},{"key":"ref_94","doi-asserted-by":"crossref","first-page":"3057","DOI":"10.1021\/jo011148j","article-title":"Peptidotriazoles on Solid Phase: [1,2,3]-Triazoles by Regiospecific Copper(I)-Catalyzed 1,3-Dipolar Cycloadditions of Terminal Alkynes to Azides","volume":"67","author":"Christensen","year":"2002","journal-title":"J. Org. Chem."},{"key":"ref_95","doi-asserted-by":"crossref","first-page":"21","DOI":"10.2174\/1871520616666160811113531","article-title":"Recent Advancements in 1,4-Disubstituted 1H-1,2,3-Triazoles as Potential Anticancer Agents","volume":"18","author":"Lal","year":"2018","journal-title":"Anti-Cancer Agents Med. Chem."},{"key":"ref_96","doi-asserted-by":"crossref","unstructured":"Alam, M.M. (2022). 1,2,3-Triazole Hybrids as Anticancer Agents: A Review. Arch. Pharm., 355.","DOI":"10.1002\/ardp.202100158"},{"key":"ref_97","doi-asserted-by":"crossref","unstructured":"Shaik, K.M., Pandurangan, K., Allaka, T.R., Nalla, S., Ganta, S., Ahmed, M.Z., Venkatesan, S., and Kishore, P.V.V.N. (2025). Novel Purine-Linked 1,2,3-Triazole Derivatives as Effective Anticancer Agents: Design, Synthesis, Docking, DFT, and ADME-T Investigations. Sci. Rep., 15.","DOI":"10.1038\/s41598-025-95669-5"},{"key":"ref_98","doi-asserted-by":"crossref","first-page":"3697","DOI":"10.1016\/j.bmcl.2013.05.023","article-title":"Synthesis and Biological Evaluation of Novel Benzoxazinyl-Oxazolidinones as Potential Antibacterial Agents","volume":"23","author":"Guo","year":"2013","journal-title":"Bioorg. Med. Chem. Lett."},{"key":"ref_99","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1016\/j.cclet.2015.11.003","article-title":"1,2,3-Triazole Incorporated Coumarin Derivatives as Potential Antifungal and Antioxidant Agents","volume":"27","author":"Shaikh","year":"2016","journal-title":"Chin. Chem. Lett."},{"key":"ref_100","doi-asserted-by":"crossref","first-page":"399","DOI":"10.3851\/IMP3387","article-title":"Antiviral Activity of 1,4-Disubstituted-1,2,3-Triazoles against HSV-1 in Vitro","volume":"25","author":"Viegas","year":"2020","journal-title":"Antivir. Ther."},{"key":"ref_101","doi-asserted-by":"crossref","first-page":"1104","DOI":"10.1039\/C5MD00057B","article-title":"1,2,3-Triazole Derivatives as Antitubercular Agents: Synthesis, Biological Evaluation and Molecular Docking Study","volume":"6","author":"Shaikh","year":"2015","journal-title":"MedChemComm"},{"key":"ref_102","doi-asserted-by":"crossref","first-page":"1345","DOI":"10.1016\/j.ejmech.2017.10.034","article-title":"Novel Indole and Triazole Based Hybrid Molecules Exhibit Potent Anti-Adipogenic and Antidyslipidemic Activity by Activating Wnt3a\/\u03b2-Catenin Pathway","volume":"143","author":"Rajan","year":"2018","journal-title":"Eur. J. Med. Chem."},{"key":"ref_103","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1111\/j.1535-7511.2009.01336.x","article-title":"Rufinamide: A Novel Broad-Spectrum Antiepileptic Drug","volume":"10","author":"Wheless","year":"2010","journal-title":"Epilepsy Curr."},{"key":"ref_104","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1007\/s10549-018-4813-z","article-title":"Phase 1 Study of Seviteronel, a Selective CYP17 Lyase and Androgen Receptor Inhibitor, in Women with Estrogen Receptor-Positive or Triple-Negative Breast Cancer","volume":"171","author":"Bardia","year":"2018","journal-title":"Breast Cancer Res. Treat."},{"key":"ref_105","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1016\/j.nurt.2006.11.006","article-title":"Rufinamide","volume":"4","author":"Arroyo","year":"2007","journal-title":"Neurotherapeutics"},{"key":"ref_106","doi-asserted-by":"crossref","first-page":"6542","DOI":"10.1021\/acs.jmedchem.3c00442","article-title":"Non-Steroidal CYP17A1 Inhibitors: Discovery and Assessment","volume":"66","author":"Pandey","year":"2023","journal-title":"J. Med. Chem."},{"key":"ref_107","doi-asserted-by":"crossref","unstructured":"Cao, Z., Zhang, J., Guo, M., Shao, B., Wei, X., Li, S., Wang, P., and Zhai, X. (2023). Discovery of Novel Phenyl Triazole Analogs as TRK\/ALK Dual Inhibitors with Prospective Antitumor Effects. Bioorg. Chem., 136.","DOI":"10.1016\/j.bioorg.2023.106563"},{"key":"ref_108","doi-asserted-by":"crossref","first-page":"2419","DOI":"10.1007\/s00044-023-03132-9","article-title":"Synthesis, in-Silico Based Virtual Screening, Anti-Cancer Potential of Novel1,2,3-Triazole-Thiadiazole Hybrid Derivatives as Aurora Kinase A (ARK-A) and Extracellular Regulated Kinase 2 (ERK2) Dual Inhibitors","volume":"32","author":"Bontha","year":"2023","journal-title":"Med. Chem. Res."},{"key":"ref_109","doi-asserted-by":"crossref","first-page":"66595","DOI":"10.1039\/C6RA09717K","article-title":"Design and Synthesis of Novel Dual-Target Agents for HDAC1 and CK2 Inhibition","volume":"6","author":"Purwin","year":"2016","journal-title":"RSC Adv."},{"key":"ref_110","doi-asserted-by":"crossref","unstructured":"Shanmugam, G., Rakshit, S., and Sarkar, K. (2022). HDAC Inhibitors: Targets for Tumor Therapy, Immune Modulation and Lung Diseases. Transl. Oncol., 16.","DOI":"10.1016\/j.tranon.2021.101312"},{"key":"ref_111","doi-asserted-by":"crossref","unstructured":"Elsebaie, H.A., Abdulla, M.-H., Elsayed, Z.M., Shaldam, M.A., Tawfik, H.O., Morsy, S.N., Mohammed, M.-A.V., Bin Traiki, T., Elkaeed, E.B., and Abdel-Aziz, H.A. (2024). Unveiling the Potential of Isatin-Grafted Phenyl-1,2,3-Triazole Derivatives as Dual VEGFR-2\/STAT-3 Inhibitors: Design, Synthesis and Biological Assessments. Bioorg. Chem., 151.","DOI":"10.1016\/j.bioorg.2024.107626"},{"key":"ref_112","doi-asserted-by":"crossref","unstructured":"Lavunuri, S., Nadh, R.V., Banothu, D., and Rapeti, S.K. (2024). Synthesis of Quinoline Fused 1,2,3-Triazole Derivatives via Continuous CuAAC and C-H Arylation; Anti-Breast Cancer, Anti-EGFR and HER2 Activities, Computational Studies. Tetrahedron Lett., 150.","DOI":"10.1016\/j.tetlet.2024.155282"},{"key":"ref_113","doi-asserted-by":"crossref","first-page":"1208","DOI":"10.1039\/D4MD00750F","article-title":"Dual EGFR and Telomerase Inhibitory Potential of New Triazole Tethered Schiff Bases Endowed with Apoptosis: Design, Synthesis, and Biological Assessments","volume":"16","author":"Zeidan","year":"2025","journal-title":"RSC Med. Chem."},{"key":"ref_114","doi-asserted-by":"crossref","unstructured":"Mardaneh, P., Pirhadi, S., Mohabbati, M., Khoshneviszadeh, M., Rezaei, Z., Saso, L., Edraki, N., and Firuzi, O. (2025). Design, Synthesis and Pharmacological Evaluation of 1,4-Naphthoquinone-1,2,3-Triazole Hybrids as New Anticancer Agents with Multi-Kinase Inhibitory Activity. Sci. Rep., 15.","DOI":"10.1038\/s41598-025-87483-w"},{"key":"ref_115","doi-asserted-by":"crossref","unstructured":"Abbas, H.-A.S., Nossier, E.S., El-Manawaty, M.A., and El-Bayaa, M.N. (2024). New Sulfonamide-Based Glycosides Incorporated 1,2,3-Triazole as Cytotoxic Agents through VEGFR-2 and Carbonic Anhydrase Inhibitory Activity. Sci. Rep., 14.","DOI":"10.1038\/s41598-024-62864-9"},{"key":"ref_116","doi-asserted-by":"crossref","first-page":"591","DOI":"10.1517\/17460441.2015.1038235","article-title":"Designing Carbonic Anhydrase Inhibitors for the Treatment of Breast Cancer","volume":"10","author":"Supuran","year":"2015","journal-title":"Expert Opin. Drug Discov."},{"key":"ref_117","doi-asserted-by":"crossref","first-page":"20060","DOI":"10.1021\/acs.jmedchem.5c00736","article-title":"Dual Transcriptional Repression of Oncogenic c-KIT and KRAS by G4-Targeting Triazolyl-Indole Scaffolds Induces Synthetic Lethality in Leukemia Cells","volume":"68","author":"Bhattacharyya","year":"2025","journal-title":"J. Med. Chem."},{"key":"ref_118","doi-asserted-by":"crossref","unstructured":"Matin, M.M., Matin, P., Rahman, R., Ben Hadda, T., Almalki, F.A., Mahmud, S., Ghoneim, M.M., Alruwaily, M., and Alshehri, S. (2022). Triazoles and Their Derivatives: Chemistry, Synthesis, and Therapeutic Applications. Front. Mol. Biosci., 9.","DOI":"10.3389\/fmolb.2022.864286"},{"key":"ref_119","doi-asserted-by":"crossref","unstructured":"Hamoud, M.M.S., Osman, N.A., Rezq, S., Abd El-wahab, H.A., Hassan, A.E.A., Abdel-Fattah, H.A., Romero, D.G., and Ghanim, A.M. (2022). Design and Synthesis of Novel 1,3,4-Oxadiazole and 1,2,4-Triazole Derivatives as Cyclooxygenase-2 Inhibitors with Anti-Inflammatory and Antioxidant Activity in LPS-Stimulated RAW264.7 Macrophages. Bioorg. Chem., 124.","DOI":"10.1016\/j.bioorg.2022.105808"},{"key":"ref_120","doi-asserted-by":"crossref","first-page":"11943","DOI":"10.1021\/acsomega.1c00424","article-title":"Synthesis, Hemolytic Studies, and In Silico Modeling of Novel Acefylline\u20131,2,4-Triazole Hybrids as Potential Anti-Cancer Agents against MCF-7 and A549","volume":"6","author":"Shahzadi","year":"2021","journal-title":"ACS Omega"},{"key":"ref_121","doi-asserted-by":"crossref","unstructured":"Han, M.\u0130., Bek\u00e7i, H., Uba, A.I., Y\u0131ld\u0131r\u0131m, Y., Karasulu, E., Cumao\u011flu, A., Karasulu, H.Y., Yelek\u00e7i, K., Y\u0131lmaz, \u00d6., and K\u00fc\u00e7\u00fckg\u00fczel, \u015e.G. (2019). Synthesis, Molecular Modeling, in Vivo Study, and Anticancer Activity of 1,2,4-triazole Containing Hydrazide\u2013Hydrazones Derived from (S)-naproxen. Arch. Pharm., 352.","DOI":"10.1002\/ardp.201800365"},{"key":"ref_122","doi-asserted-by":"crossref","first-page":"274","DOI":"10.1016\/j.ejmech.2019.04.043","article-title":"Antibacterial Activity Study of 1,2,4-Triazole Derivatives","volume":"173","author":"Gao","year":"2019","journal-title":"Eur. J. Med. Chem."},{"key":"ref_123","doi-asserted-by":"crossref","first-page":"961","DOI":"10.1080\/14787210.2021.1865801","article-title":"Fostemsavir for the Treatment of HIV","volume":"19","author":"Seval","year":"2021","journal-title":"Expert Rev. Anti. Infect. Ther."},{"key":"ref_124","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1016\/j.virusres.2004.11.006","article-title":"Metabolism and Antiviral Activity of Ribavirin","volume":"107","author":"Parker","year":"2005","journal-title":"Virus Res."},{"key":"ref_125","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1111\/j.1470-9465.2004.00841.x","article-title":"History of the Development of Azole Derivatives","volume":"10","author":"Maertens","year":"2004","journal-title":"Clin. Microbiol. Infect."},{"key":"ref_126","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1016\/j.ejps.2018.12.018","article-title":"Development of the 1,2,4-Triazole-Based Anticonvulsant Drug Candidates Acting on the Voltage-Gated Sodium Channels. Insights from in-Vivo, in-Vitro, and in-Silico Studies","volume":"129","author":"Siwek","year":"2019","journal-title":"Eur. J. Pharm. Sci."},{"key":"ref_127","doi-asserted-by":"crossref","unstructured":"Quattrini, L., Coviello, V., Sartini, S., Di Desidero, T., Orlandi, P., Ke, Y.-Y., Liu, K.-L., Hsieh, H.-P., Bocci, G., and La Motta, C. (2019). Dual Kit\/Aur Inhibitors as Chemosensitizing Agents for the Treatment of Melanoma: Design, Synthesis, Docking Studies and Functional Investigation. Sci. Rep., 9.","DOI":"10.1038\/s41598-019-46287-5"},{"key":"ref_128","doi-asserted-by":"crossref","first-page":"1485","DOI":"10.1007\/s40265-019-01188-9","article-title":"Selinexor: First Global Approval","volume":"79","author":"Syed","year":"2019","journal-title":"Drugs"},{"key":"ref_129","doi-asserted-by":"crossref","first-page":"1059","DOI":"10.1038\/bjc.2011.58","article-title":"Differences between the Non-Steroidal Aromatase Inhibitors Anastrozole and Letrozole\u2013of Clinical Importance?","volume":"104","author":"Geisler","year":"2011","journal-title":"Br. J. Cancer"},{"key":"ref_130","doi-asserted-by":"crossref","first-page":"957","DOI":"10.1007\/s40262-021-01016-y","article-title":"Pharmacokinetics of Selinexor: The First-in-Class Selective Inhibitor of Nuclear Export","volume":"60","author":"Bader","year":"2021","journal-title":"Clin. Pharmacokinet."},{"key":"ref_131","doi-asserted-by":"crossref","unstructured":"Abd-Rabbo, H., Abdel-Rahim, S., Bakr, M., Mohammed, M., and Nosseir, O. (2025). Molecular Docking and ADME Calculations of Structurally Similar Compounds to Anastrozole. Trends Adv. Sci. Technol., 2.","DOI":"10.62537\/2974-444X.1036"},{"key":"ref_132","doi-asserted-by":"crossref","first-page":"45665","DOI":"10.1021\/acsomega.2c06531","article-title":"Synthesis of New Bioactive Indolyl-1,2,4-Triazole Hybrids as Dual Inhibitors for EGFR\/PARP-1 Targeting Breast and Liver Cancer Cells","volume":"7","author":"Youssef","year":"2022","journal-title":"ACS Omega"},{"key":"ref_133","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1016\/j.ebiom.2018.11.025","article-title":"High PARP-1 Expression Predicts Poor Survival in Acute Myeloid Leukemia and PARP-1 Inhibitor and SAHA-Bendamustine Hybrid Inhibitor Combination Treatment Synergistically Enhances Anti-Tumor Effects","volume":"38","author":"Li","year":"2018","journal-title":"EBioMedicine"},{"key":"ref_134","doi-asserted-by":"crossref","unstructured":"Wei, H., Duan, Y., Gou, W., Cui, J., Ning, H., Li, D., Qin, Y., Liu, Q., and Li, Y. (2019). Design, Synthesis and Biological Evaluation of Novel 4-Anilinoquinazoline Derivatives as Hypoxia-Selective EGFR and VEGFR-2 Dual Inhibitors. Eur. J. Med. Chem., 181.","DOI":"10.1016\/j.ejmech.2019.07.055"},{"key":"ref_135","doi-asserted-by":"crossref","unstructured":"Mustafa, M., Abd El-Hafeez, A.A., Abdelhamid, D., Katkar, G.D., Mostafa, Y.A., Ghosh, P., Hayallah, A.M., and Abuo-Rahma, G.E.-D.A. (2021). A First-in-Class Anticancer Dual HDAC2\/FAK Inhibitors Bearing Hydroxamates\/Benzamides Capped by Pyridinyl-1,2,4-Triazoles. Eur. J. Med. Chem., 222.","DOI":"10.1016\/j.ejmech.2021.113569"},{"key":"ref_136","doi-asserted-by":"crossref","first-page":"598","DOI":"10.1038\/nrc3792","article-title":"FAK in Cancer: Mechanistic Findings and Clinical Applications","volume":"14","author":"Sulzmaier","year":"2014","journal-title":"Nat. Rev. Cancer"},{"key":"ref_137","doi-asserted-by":"crossref","unstructured":"El-Sayed, W.A., Alminderej, F.M., Mounier, M.M., Nossier, E.S., Saleh, S.M., and Kassem, A.F. (2022). New 1,2,3-Triazole-Coumarin-Glycoside Hybrids and Their 1,2,4-Triazolyl Thioglycoside Analogs Targeting Mitochondria Apoptotic Pathway: Synthesis, Anticancer Activity and Docking Simulation. Molecules, 27.","DOI":"10.3390\/molecules27175688"},{"key":"ref_138","doi-asserted-by":"crossref","first-page":"32978","DOI":"10.1039\/D4RA06394E","article-title":"Design, Synthesis, and Biological Evaluation of Novel Quinoline-Based EGFR\/HER-2 Dual-Target Inhibitors as Potential Anti-Tumor Agents","volume":"14","author":"Tawfeek","year":"2024","journal-title":"RSC Adv."},{"key":"ref_139","doi-asserted-by":"crossref","unstructured":"Mohassab, A.M., Hassan, H.A., Abdelhamid, D., Gouda, A.M., Youssif, B.G.M., Tateishi, H., Fujita, M., Otsuka, M., and Abdel-Aziz, M. (2021). Design and Synthesis of Novel Quinoline\/Chalcone\/1,2,4-Triazole Hybrids as Potent Antiproliferative Agent Targeting EGFR and BRAFV600E Kinases. Bioorg. Chem., 106.","DOI":"10.1016\/j.bioorg.2020.104510"},{"key":"ref_140","doi-asserted-by":"crossref","unstructured":"Mohassab, A.M., Youssif, B.G.M., Alzahrani, A.Y.A., Abou-Zied, H.A., Br\u00e4se, S., Abdel-Aal, M.A.A., Abdelrahman, K.S., and Abbas, S.H. (2026). Design and Synthesis of Novel Thiazole\/1,2,4-Triazole\/Quinoline Hybrids as Antiproliferative Agents, Apoptosis Inducers, Immunomodulators, and Multi-EGFR\/BRAFV600E\/HER-2 Inhibitors. Mol. Divers.","DOI":"10.1007\/s11030-026-11467-9"},{"key":"ref_141","doi-asserted-by":"crossref","first-page":"10558","DOI":"10.1021\/acs.jmedchem.3c00721","article-title":"1,5-Diaryl-1,2,4-Triazole Ureas as New SLC-0111 Analogues Endowed with Dual Carbonic Anhydrase and VEGFR-2 Inhibitory Activities","volume":"66","author":"Elsawi","year":"2023","journal-title":"J. Med. Chem."}],"container-title":["International Journal of Molecular Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1422-0067\/27\/10\/4172\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,19]],"date-time":"2026-05-19T04:18:16Z","timestamp":1779164296000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1422-0067\/27\/10\/4172"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,7]]},"references-count":141,"journal-issue":{"issue":"10","published-online":{"date-parts":[[2026,5]]}},"alternative-id":["ijms27104172"],"URL":"https:\/\/doi.org\/10.3390\/ijms27104172","relation":{},"ISSN":["1422-0067"],"issn-type":[{"value":"1422-0067","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,5,7]]}}}